<DOC>
	<DOC>NCT02097121</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of onabotulinumtoxinA (BOTOXÂ®) for the treatment of urinary incontinence due to overactive bladder in pediatric patients between the ages of 12 to 17 years who have not been adequately managed with anticholinergics.</brief_summary>
	<brief_title>OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Symptoms of overactive bladder (OAB) (frequency/urgency) with urinary incontinence for at least 6 months OAB symptoms not adequately managed by 1 or more anticholinergic agents OAB caused by a neurological condition Use of anticholinergics or other medications to treat OAB symptoms within 7 days Current use of indwelling catheter or clean intermittent catheterization to empty the bladder Previous or current use of botulinum toxin therapy of any serotype for any urological condition, or treatment with botulinum toxin of any serotype within 3 months for any other condition or use Myasthenia gravis, EatonLambert syndrome, or amyotrophic lateral sclerosis</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>